Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24832 | 0.80 | — | — | |
| SCHEMBL9578962 | 0.79 | — | — | |
| SCHEMBL11373051 | 0.77 | — | — | |
| SCHEMBL15756046 | 0.77 | — | — | |
| SCHEMBL11374156 | 0.77 | — | — | |
| SCHEMBL127488 | 0.77 | TSHR (0.38) | KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11369970 | 0.77 | — | — | |
| SCHEMBL6528243 | 0.74 | OPRK1 (0.38) | KDM4EMEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9501246 | 0.74 | OPRK1 (0.36) | KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15756055 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1587 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501813-B1 | Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them | ALBIREO AB (SE) | 2013-08-14 | — | — | EP | claimed |
| US-8067584-B2 | Benzothiazepine derivatives | ALBIREO AB (SE) | 2011-11-29 | — | — | US | claimed |
| EP-1539743-B1 | PYRAZOLE DERIVATIVES AS GNRH INHIBITORS | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | claimed |
| US-6362191-B1 | ANTIBIOTICS | ZENECA LTD. (GB) | 2002-03-26 | — | — | US | claimed |
| WO-2024140970-A1 | BICYCLIC COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | 广州市联瑞制药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024140968-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | 广州市联瑞制药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024140969-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | 广州市联瑞制药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024140971-A1 | BICYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 广州市联瑞制药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| US-12023319-B2 | Carboxylic acid aromatic amides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-07-02 | — | — | US | disclosed |
| CN-118271300-A | Lactam compound, and preparation method and application thereof | 广州市联瑞制药有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271299-A | Lactam compound, and preparation method and application thereof | 广州市联瑞制药有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA (ES) | 2024-06-11 | — | — | US | disclosed |
| US-5834468-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANALGESICS TREATING RHEUMATIC DISEASE, BONE DISORDER, INJURIES | ZENECA LIMITED (GB) | 1998-11-10 | — | — | US | disclosed |
| WO-1997043280-A1 | 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS | ZENECA LIMITED (GB) | 1997-11-20 | — | — | WO | disclosed |
| WO-1997031917-A9 | SUBSTITUTED PHENYLOXAZOLIDINONES AND THEIR USE AS ANTIBIOTICS | — | 1997-10-30 | — | — | WO | disclosed |
| WO-1997031917-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES AND THEIR USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997030995-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997000863-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1997-01-09 | — | — | WO | disclosed |
| WO-1997000864-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1997-01-09 | — | — | WO | disclosed |
| EP-0752421-A1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ZENECA LIMITED (GB) | 1997-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12023319-B2 | Carboxylic acid aromatic amides | DDC, PAH, NAT1 | KDM4E 1120/4885MEN1 2258/4885KMT2A 1098/4885 |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | UGT1A3, UGT1A1, UGT1A6 | KDM4E 1983/4885MEN1 689/4885KMT2A 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.